I initiated coverage on Senesco (OTCQB:SNTI) four months ago when it was trading at $3. Shares rose above $7, but have since retreated. This provides an ideal opportunity for investors because since my last article, 2 positive events have occurred:
Number 1: Senesco just reported excellent data for cohort 3 of the current clinical trial. This milestone event takes Senesco one step closer to addressing the $75 billion cancer drug market.
Number 2: Opko's (OPK), Dr. Phillip Frost just initiated a 9.99% position in Senesco. As some of my readers know, all my Dr. Frost investments have provided returns above 100%. For example, soon after Dr. Frost initiated a position in MusclePharm (OTCQB:...
Only subscribers can access this article, which is part of the PRO research library covering 3,619 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: